Перегляд вихідного коду сторінки The Latest INCB28060 Is Twice The Fun

Although a causal relationship cannot be definitively excluded, this imbalance may well be attributed to detection bias due to frequent urinalyses in dapagliflozin-treated patients experiencing urinary tract infections. As a precautionary measure, co-administration of dapagliflozin with pioglitazone is not currently recommended in Europe [European Medicines Agency, 2014a]. Dapagliflozin in special populations Renal impairment Dapagliflozin is not recommended for use in patients with moderate to severe renal impairment [estimated glomerular filtration rate (eGFR) [http://en.wikipedia.org/wiki/Isotretinoin Isotretinoin] for dapagliflozin 10 mg) and an imbalance in incidence of bone fractures among the two groups (13 patients treated with dapagliflozin, n = 168 versus zero events in the placebo group, n = 84) after two years of treatment [Kohan et [http://www.selleckchem.com/products/gdc-0068.html GDC-0068 ic50] al. 2014]. Elderly patients Glycemic efficacy of dapagliflozin in elderly subjects has been explored in a pooled analysis of 12 phase IIb/III studies. The effect of dapagliflozin on HbA1c was slightly attenuated in patients ?65 years of age compared with those [http://www.selleckchem.com/products/incb28060.html INCB28060 nmr] amongst elderly subjects, patients with moderate renal impairment or subjects treated with loop diuretics [European Medicines Agency, 2012]. Discontinuation of treatment with dapagliflozin is recommended for patients who develop volume depletion. Are the benefits worth the costs? T2DM is a chronic and costly disease with an increasing prevalence in both developed and developing countries. Therapeutic interventions that delay or prevent the development of its long-term complications could confer substantial cost savings to health systems worldwide, which are forced to allocate limited healthcare resources efficiently and evenly among the population [Oliver et al. 2004]. As a consequence, many countries have adopted the implementation of Health Technology Assessments (HTAs) and economic evaluations in the decision-making process for reimbursement of new health technologies [Oliver et al. 2004; Brennan et al. 2006].